Clinical Efficacy and Real-World Impact
In 2026, data from real-world implementation in countries like Ghana, Kenya, and Malawi confirms that the vaccines perform as effectively in community settings as they did in controlled clinical trials.
Both RTS,S and R21 have demonstrated the ability to reduce symptomatic malaria cases by more than 50% during the first year of vaccination. Most critically, when these vaccines are administered in areas with highly seasonal transmission, their efficacy can reach up to 75% if timed correctly before the peak rainy season. Large-scale pilot data now shows a 13% drop in all-cause mortality among age-eligible children, proving that these vaccines are one of the most powerful tools currently available for increasing child survival in endemic regions.